N-Methylformamide (NMF), currently under-going phase II clinical evaluation for the treatment of cancer, and the established antitumour agent cis-platinum (CDDP) have nonoverlapping toxicities, with the exception of gastrointestinal side effects. The major target organs for the toxicities of the compounds are the liver (NMF) and the kidney (CDDP). Furthermore, NMF is nonleukopenic. In view of this, and of recent evidence that NMF enhances the cytotoxic effect of CDDP in vitro the activity of NMF and CDDP against the M5076 sarcoma implanted in mice was investigated, together with the various toxicities in mice and rats. The antitumour effect of NMF in combination with CDDP was additive, but NMF did not alter the leukopenia produced by CDDP in the tumour-bearing mice. CDDP produced only a minimal increase in the hepatotoxicity of NMF in mice, and NMF did not augment the nephrotoxicity of CDDP in rats (except for a small effect on calcium excretion). The results support suggestions that clinical evaluation of combination chemotherapy with NMF and CDDP is warranted.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Blachley JD, Hill JB (1981) Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95:628
Buamah PK, Howell A, Whitby H, Harpur ES, Gescher A (1982) Assessment of renal function during high dose cis-platinum therapy in patients with ovarian carcinoma. Cancer Chemother Pharmacol 8:281
Clarke CA, Phillips FS, Sternberg RK, Barclay RK, Stock CC (1953) Effects of N-methylformamide and related compounds in sarcoma 180. Proc Soc Exp Biol Med 84:203
Collins SJ, Ruscetti FW, Gallagher RE, Gallo RC (1978) Terminal differentiation of human promyelocytic leukaemia cells induced by dimethyl sulphoxide and other polar solvents. Proc Natl Acad Sci USA 75:2458
Davis S, Kessler W, Haddad BM, Maesaka JK (1980) Acute renal tubular dysfunction following cis-dichlorodiammine-platinum therapy. J Med 11:133
Dentino M, Luft FC, Yum MN, Williams SD, Einhorn LH (1978) Long term effect of cis-diamminedichloride platinum (CDDP) on renal function and structure in man. Cancer 41: 1274
Dexter DL, Spremulli EN, Matook GM, Diamond E, Calabresi P (1982) Inhibition of the growth of human colon cancer xenografts by polar solvents. Cancer Res 42:5018
Dexter DL, De Fusco DJ, McCarthy K, Calabresi P (1983) Polar solvents increase the sensitivity of cultured human colon cancer cells to cisplatinum and mitomycin-C. Proc Am Assoc Cancer Res 24:267
Dexter DL, Lee ES, Bliven S, Glicksman AS, Leith JT (1984) Enhancement by N-methylformamide of the effects of photon irradiation on a human colon cancer xenograft. Proc Am Assoc Cancer Res 25:321
Jones BR, Bhalla RB, Mladek J, Kaleya RN, Gralla RJ, Alcock NW, Schwartz MK, Young CW, Reidenberg MM (1980) Comparison of methods of evaluating nephrotoxicity of cis-platinum. Clin Pharmacol Ther 27:557
Kachmar JF, Moss DW (1976) Enzymes: In: Teitz NW (ed) Fundamentals of clinical chemistry. Saunders, Philadelphia, p 672
Langdon SP, Hickman JA, Gescher A, Stevens MFG, Chubb D, Vickers LM (1983) N-Methylformamide (NSC 3051): a potential candidate for combination chemotherapy. Eur J Cancer Clin Oncol 21:745
Langdon SP, Gescher A, Hickman JA, Stevens MFG (1984) The chemosensitivity of a new experimental model — the M5076 reticulum cell sarcoma. Eur J Cancer Clin Oncol 20: 699
Leathwood PD, Plummer DT (1969) Enzymes in rat urine: I. A metabolism cage for the complete separation of urine and faeces. Enzymologica 37:240
Litchfield JT, Wilcoxon F (1949) A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 96:99
Lowry OH, Rosenbrough NJ, Farr Al, Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265
Luft FC, Patel V (1979) Lysosomal acid hydrolases as urinary markers of aminoglycoside nephrotoxicity in the rat. In: Fillastre J-P (ed) Colloque international — Nephrotoxicity. Interactions of drugs with membrane systems, mitochondria and lysosomes. Masson, New York, p 127
McVie JG, ten Bokkel Huinink WW, Simonetti G, Dubbelman R (1984) Phase I trial of N-methylformamide. Cancer Treat Rep 68:607
Meyers WPL, Karnofsky D, Burchenal JH (1956) The hepatotoxic action of N-methylformamide in man. Cancer 9:949
Mondorf AW, Kinne R, Scherberich JE, Falkenberg F (1972) Isolierung enzymatische und immunologische Characterisierung einer Plasmamembranfraktion vom proximalen Tubulus der menschlichen Niere. Clin Chim Acta 37:25
Newman KN, Meeks RG, Frick S (1981) Phase I report of task I preclinical intravenous toxicity study of N-methylformamide (NSC 3051) in CDF1 mice and beagle dogs. Southern Research Institute, Birmingham, Ala
Nitschke R (1981) Renal and electrolyte disturbances associated with cisplatin. Ann Intern Med 95:628
Rose CI, Henderson AR (1975) Reaction rate assay of serum sorbitol dehydrogenase activity at 37°C. Clin Chem 21:1619
Schilsky RL, Anderson T (1979) Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med 90:929
Ward JM, Young DM, Fauvie KA, Wolpert MK, Davis R, Guarino AM (1976) Comparative nephrotoxicity of platinum cancer chemotherapeutic agents. Cancer Treat Rep 60:1675
Whitby H, Chahwala SB, Gescher A (1984a) The effect of N-methylformamide (NSC 3051) on the uptake of calcium by mouse liver microsomes and mitochondria. Proc Am Assoc Cancer Res 25:380
Whitby H, Gescher A, Levy L (1984b) An investigation of the mechanism of hepatotoxicity of the antitumor agent N-methylformamide in mice. Biochem Pharmacol 33:295
About this article
Cite this article
Harpur, E.S., Langdon, S.P., Fathalla, S.A.K. et al. The antitumour effect and toxicity of cis-platinum and N-methylformamide in combination. Cancer Chemother. Pharmacol. 16, 139–147 (1986). https://doi.org/10.1007/BF00256164
- Clinical Evaluation
- Cytotoxic Effect
- Target Organ